CLIMB BIO INC. - COMMON STOCK

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

09 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Climb Bio to be Added to the Nasdaq Biotechnology Index

19 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Climb Bio to Present at Upcoming Investor Conferences

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

11 Oct 2024 12:30:00 By Nasdaq GlobeNewswire

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

04 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Climb Bio to Host Virtual Investor Event on October 15, 2024

03 Oct 2024 10:00:16 By Nasdaq GlobeNewswire

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

02 Oct 2024 09:00:23 By Nasdaq GlobeNewswire

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

11 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Announces Additions to its Leadership Team

26 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Reports Second Quarter Financial Results

14 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

28 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

27 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

11 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

20 Jul 2023 06:45:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

11 May 2023 16:10:00 By Nasdaq GlobeNewswire

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

06 Mar 2023 16:10:00 By Nasdaq GlobeNewswire